CA2494473C - Compositions de proteines stabilisees pour administration topique et methodes pour les produire - Google Patents

Compositions de proteines stabilisees pour administration topique et methodes pour les produire Download PDF

Info

Publication number
CA2494473C
CA2494473C CA002494473A CA2494473A CA2494473C CA 2494473 C CA2494473 C CA 2494473C CA 002494473 A CA002494473 A CA 002494473A CA 2494473 A CA2494473 A CA 2494473A CA 2494473 C CA2494473 C CA 2494473C
Authority
CA
Canada
Prior art keywords
botulinum toxin
composition
agent
formulation
elastin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002494473A
Other languages
English (en)
Other versions
CA2494473A1 (fr
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DPM Therapeutics Corp
Original Assignee
DPM Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DPM Therapeutics Corp filed Critical DPM Therapeutics Corp
Priority to CA002494473A priority Critical patent/CA2494473C/fr
Publication of CA2494473A1 publication Critical patent/CA2494473A1/fr
Priority to PCT/CA2006/000167 priority patent/WO2006084353A1/fr
Priority to DK06705123.5T priority patent/DK1853303T3/en
Priority to PL06705123T priority patent/PL1853303T3/pl
Priority to ES06705123.5T priority patent/ES2562494T3/es
Priority to EP06705123.5A priority patent/EP1853303B1/fr
Priority to PT67051235T priority patent/PT1853303E/pt
Application granted granted Critical
Publication of CA2494473C publication Critical patent/CA2494473C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La préparation stabilisante, qui augmente également la perméation, est destinée à l'administration locale ou transdermique d'un principe actif. Ladite préparation comprend du collagène, de l'élastine, du sphingoside et du cérébroside. L'invention porte également sur des formules pharmaceutiques ou cosmétiques comprenant une quantité active d'un principe actif ainsi que la préparation stabilisante, de même que des méthodes d'administration de principes actifs par voie topique ou transdermique.
CA002494473A 2005-02-14 2005-02-14 Compositions de proteines stabilisees pour administration topique et methodes pour les produire Expired - Fee Related CA2494473C (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002494473A CA2494473C (fr) 2005-02-14 2005-02-14 Compositions de proteines stabilisees pour administration topique et methodes pour les produire
PCT/CA2006/000167 WO2006084353A1 (fr) 2005-02-14 2006-02-08 Préparations stabilisées pour administration locale et méthodes d'élaboration desdites préparations
DK06705123.5T DK1853303T3 (en) 2005-02-14 2006-02-08 STABILIZED COMPOSITIONS FOR TOPIC ADMINISTRATION AND PROCEDURES FOR PREPARING IT
PL06705123T PL1853303T3 (pl) 2005-02-14 2006-02-08 Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania
ES06705123.5T ES2562494T3 (es) 2005-02-14 2006-02-08 Composiciones estabilizadas para administración tópica y métodos para preparar las mismas
EP06705123.5A EP1853303B1 (fr) 2005-02-14 2006-02-08 Préparations stabilisées pour administration locale et méthodes d'elaboration desdites préparations
PT67051235T PT1853303E (pt) 2005-02-14 2006-02-08 Composições estabilizadas para administração tópica, e métodos para a sua preparação

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002494473A CA2494473C (fr) 2005-02-14 2005-02-14 Compositions de proteines stabilisees pour administration topique et methodes pour les produire

Publications (2)

Publication Number Publication Date
CA2494473A1 CA2494473A1 (fr) 2005-04-25
CA2494473C true CA2494473C (fr) 2007-06-26

Family

ID=34468770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494473A Expired - Fee Related CA2494473C (fr) 2005-02-14 2005-02-14 Compositions de proteines stabilisees pour administration topique et methodes pour les produire

Country Status (1)

Country Link
CA (1) CA2494473C (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318181B2 (en) 2005-12-01 2012-11-27 University Of Massachusetts Lowell Botulinum nanoemulsions
US9486409B2 (en) 2006-12-01 2016-11-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9724299B2 (en) 2006-12-01 2017-08-08 Anterios, Inc. Amphiphilic entity nanoparticles
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
CN115212131B (zh) * 2022-06-16 2023-09-08 广东格烯生物科技股份有限公司 一种含有重组弹性蛋白的抗皱紧致精华及其制备方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318181B2 (en) 2005-12-01 2012-11-27 University Of Massachusetts Lowell Botulinum nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9486409B2 (en) 2006-12-01 2016-11-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US9724299B2 (en) 2006-12-01 2017-08-08 Anterios, Inc. Amphiphilic entity nanoparticles
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Also Published As

Publication number Publication date
CA2494473A1 (fr) 2005-04-25

Similar Documents

Publication Publication Date Title
US7838011B2 (en) Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) Stabilized compositions for topical administration and methods of making same
JP7230080B2 (ja) 低ｐＨを有する皮膚用組成物
US20080220021A1 (en) Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
JP2022008814A (ja) 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
US6316428B1 (en) Topical moisturizing composition and method
JP4944896B2 (ja) 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法
CA2494473C (fr) Compositions de proteines stabilisees pour administration topique et methodes pour les produire
EP1853303B1 (fr) Préparations stabilisées pour administration locale et méthodes d'elaboration desdites préparations
JP2014001211A (ja) Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
US20170361130A9 (en) Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
CA1131561A (fr) Preparation pour administration topique
US20150283080A1 (en) Stabilized dermatological delivery system for active ingredient compositions for topical administration to the skin
MX2014000612A (es) Toxinas botulinicas para usar en un metodo para el tratamiento de depositos adiposos.
GB1563824A (en) Hair growth compositions
KR20150057327A (ko) 국소 투여용 안정화된 단백질 조성물 및 이를 제조하는 방법
WO2025188317A1 (fr) Compositions et méthodes de traitement capillaire
RU2604160C1 (ru) Стабильная косметическая композиция на основе иммобилизованной гиалуронидазы и способ ее получения
HK1240854A1 (en) Injectable botulinum toxin formulations
HK40000453A (en) Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
MX2013001099A (es) Crema o gel de aplicación tópica con neurotoxina botulinica encapsulada en nanoparticulas liposomales para el tratamiento de la hiperhidrosis.
HK1162925A (en) Injectable botulinum toxin formulations
HK1128625A (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210215